DGAP-News: Nanostart-holding MagForce signs Letter of Intent with leading Russian Medical Product Distribution Company Delrus
(firmenpresse) - DGAP-News: Nanostart AG / Key word(s): Miscellaneous
Nanostart-holding MagForce signs Letter of Intent with leading Russian
Medical Product Distribution Company Delrus
14.12.2011 / 11:56
---------------------------------------------------------------------
* Plans outlined for NanoTherm(R)therapy market entry in Russia
* Financial and professional support for approval in Russia
* First step for internationalization of NanoTherm therapy
Frankfurt / Berlin - December 14, 2011 - Nanostart-holding
MagForce AG (XETRA: MF6), a leading medical technology company focusing on
nanomedicine in oncology and Delrus Inc., a leading Russian medical product
distribution company, announced today the signing of a Letter of Intent
(LOI)between the two companies.
The LOI outlines a collaboration focusing on an exclusive distribution
agreement for NanoTherm therapy in the Russian Federation and Kazakhstan.
The LOI includes Delrus' financial and professional support for the
regulatory approval of NanoTherm therapy in brain tumors and other
indications in Russia, including pancreatic and
prostate cancer.
Delrus is one of the largest and most established distributors for medical
products in Russia, working with partners like Johnson&Johnson, 3M, Nihon
Kohden, Fresenius Kabi, and many other medical products manufacturers.
With more than 2500 employees, the company
has an extensive distribution and service network to support their
marketing activities, which enables them to not only introduce new products
and technologies to the market, but also support their usage and expansion.
The Russian market is especially interesting for MagForce since it provides
access to a population of 160 million people.
'This year Delrus is celebrating its twentieth anniversary as company and
its ongoing commitment to bring the most modern and advanced technologies
to the Russian healthcare system. Our motto is 'progress in the name of
life,' which reflects the very promising potential we see in a
collaboration with MagForce,' said July Magadeev, President of Delrus. 'We
look forward to the opportunity to bring nanomedicine in oncology to the
medical market in Russia and Kazakhstan and professionally support its
usage among oncology specialists and in
hospitals.'
'I am extremely pleased that we are working together with Delrus
to establish a comprehensive collaboration to distribute NanoTherm(R)
therapy in Russia and Kazakhstan,' said Dr. Andreas Jordan, Founder and
member of the Executive Board at MagForce. 'Their experience and excellent
track record open up significant opportunities for MagForce in Central and
Eastern European markets.'
About Nanostart:
Nanostart AG,headquartered in the German financial capital of Frankfurt, is
a leading nanotechnology investment company, with portfolio companies
spanning the globe from Silicon Valley to Singapore. The company provides
venture capital financing for nanotechnology companies in various growth
phases with a focus on innovation-driven industries of the future such as
cleantech, life sciences and IT/electronics. Through its subsidiary
Nanostart Asia and the
venture capital fund in Singapore, Nanostart is proud to be the investment
partner of the Singaporean government. For further information please
visit:www.nanostart.de.
About MagForce:
MagForce AG (XETRA: MF6) is a leading medical technology company focusing
on nanomedicine in oncology. The company's proprietary procedure,
NanoTherm(R) therapy, enables the targeted treatment of solid tumors
through the intratumoral generation of heat via activation of magnetic
nanoparticles. NanoTherm(R), NanoPlan(R), and NanoActivator(TM) are
components of the therapy and have received EU-wide regulatory approval as
medical devices for the treatment of brain tumors. MagForce, NanoTherm,
NanoPlan and NanoActivator are trademarks of MagForce
AG in selected countries. For further information please visit:
www.magforce.com
About Delrus:
DELRUS, founded in 1991 with currently more than 2500 employees, is an
international science and industry holding company maintaining partnership
relations with medical product manufacturers in 30
countries. The company, among leaders in the Russian market for medical
goods and disposables, is active in the supply of medical institutions.
Delrus has regional affiliates in the 80 largest cities of Russia, Belarus,
Tajikistan, Kazakhstan, Kyrgyzstan, Uzbekistan, Azerbajan, and the Ukraine.
For more information please visit www.delrus.com/en.
Disclaimer:This notice constitutes neither an offer to sell nor a
solicitation of offers to purchase or subscribe to securities. There will
be no public offering of securities of Nanostart AG in conjunction with the
existing listing of its shares in the 'Entry Standard' segment of the
regulated unofficial market (Freiverkehr) on the Frankfurt Stock Exchange.
This notice does not constitute a securities
prospectus. Neither this notice nor the information contained within is
intended for direct or indirect distribution within Canada, Australia or
Japan.
Media contact:
Nanostart AG
Dr. Hans Joachim Duerr
Head of Corporate Communications
Goethestrasse 26-28
D-60313 Frankfurt, Germany
phone: +49 (0)69-21 93 96 111
fax: +49 (0)69-21 93 96 150
e-mail: presse(at)nanostart.de
End of Corporate News
---------------------------------------------------------------------
14.12.2011 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
149713 14.12.2011
Themen in dieser Pressemitteilung:
nanostart
holding-magforce-signs-letter-of-intent-with-leading-russian-medical-product-distribution-company-delrus
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: EquityStory
" alt="Quantum Solar Power Corp. Working Device to be Submitted for NREL Certification in early 2012
Datum: 14.12.2011 - 11:56 Uhr
Sprache: Deutsch
News-ID 96803
Anzahl Zeichen: 3254
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 246 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Nanostart-holding MagForce signs Letter of Intent with leading Russian Medical Product Distribution Company Delrus"
steht unter der journalistisch-redaktionellen Verantwortung von
Nanostart AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
